NEW ANtICOAGuLANtS IN CLINICAL PRACtICE

Anticoagulants and antiplatelet drugs are used in the prophylaxis and treatment of thrombosis complicating disease entities and surgical procedures. The above-mentioned are administered separately or in combination with one another. Heparin and aspirin are classical drugs. They are burdened with side-effects, which include hemorrhagic complications, often life-threatening. Heparin is considered as a safe drug, although not free of complications. Thrombocytopenia is one such complication often requiring the discontinuation of heparin. The above-mentioned used to be a significant problem. The physician was faced with the need to treat thrombosis without the disposal of appropriate drugs. During the past 10 years many new anticoagulants appeared on the market, fulfilling the following criteria: – efficacy without increased risk of hemorrhage, – rapid and expected activity, – easy to administer, – laboratory control is not required, considering efficacy, – relative low cost. The new anticoagulants presented in the study belong to factor Xa inhibitors and direct thrombin inhibitors.